Stay up to date

News

see all news

Proteomedix präsentiert sich an der Jahresversammlung der Schweizerischen Gesellschaft für Urologie in Interlaken.

September 23, 2021

Proteomedix and New Horizon Health Limited enter into a research and development partnership.

September 21, 2021

Publications

see all publications

Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer.

Klocker H, Golding B, Weber S, Steiner E, Tennstedt P, Keller T, Schiess R, Gillessen S, Horninger W, Steuber T. BJUI Compass. 2020;1:15–20.

Neuer diagnostischer Prozess des Prostatakarzinoms

Engeler D, Korte W, Schiess R. Pipette - Swiss Laboratory Medicine 2020;3:24-26

Events

see all events

Sep 29th-Oct 1st - SGU Jahresversammlung 2021

Interlaken, CH

Oct 1st-2nd - Sicilian-Calabrian Urology Association Meeting

Catanzaro, IT

Resources

see all resources

Application note - Implementation of Proclarix in the workflow of a clinical laboratory

Analytical validation of the Proclarix Risk Score for the diagnosis of prostate cancer

Analytical performance of automated thrombospondin-1 and cathepsin D immunoassays for prostate cancer risk assessment